268 related articles for article (PubMed ID: 23645745)
1. Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer.
Debald M; Kaiser C; Abramian A; Schildhaus HU; Locher P; Wolfgarten M; Kuhn W; Braun M
Anticancer Res; 2013 May; 33(5):1971-5. PubMed ID: 23645745
[TBL] [Abstract][Full Text] [Related]
2. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
3. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
[TBL] [Abstract][Full Text] [Related]
5. Invasive lobular carcinoma of the breast: role of endothelial lymphatic marker D2-40.
Laser J; Cangiarella J; Singh B; Melamed J; Chiriboga L; Yee H; Darvishian F
Ann Clin Lab Sci; 2008; 38(2):99-104. PubMed ID: 18469353
[TBL] [Abstract][Full Text] [Related]
6. [Expression of Ezrin and E-cadherin in invasive ductal breast cancer and their correlations to lymphatic metastasis].
Li Q; Wu MF; Song AP; Wei JC; Xu G; Lu YP; Ma D
Ai Zheng; 2006 Mar; 25(3):363-6. PubMed ID: 16536996
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
10. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
11. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.
Yoshida R; Kimura N; Harada Y; Ohuchi N
Int J Oncol; 2001 Mar; 18(3):513-20. PubMed ID: 11179480
[TBL] [Abstract][Full Text] [Related]
12. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
Harigopal M; Berger AJ; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jun; 11(11):4083-9. PubMed ID: 15930343
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
[TBL] [Abstract][Full Text] [Related]
14. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases?
Goldstein NS
Am J Clin Pathol; 2002 Sep; 118(3):425-34. PubMed ID: 12219785
[TBL] [Abstract][Full Text] [Related]
15. Role of E-cadherins in development of lymphatic tumor emboli.
Gupta A; Deshpande CG; Badve S
Cancer; 2003 May; 97(9):2341-7. PubMed ID: 12712492
[TBL] [Abstract][Full Text] [Related]
16. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
17. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance].
Ma YH; Wang K; Li L; Lu ZH; Chen J
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391
[TBL] [Abstract][Full Text] [Related]
18. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Markopoulos C; Gogas J; Kittas C
Cancer; 2002 May; 94(9):2454-65. PubMed ID: 12015771
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
[TBL] [Abstract][Full Text] [Related]
20. [Expression of E-cadherine as a differential diagnostic fest for lobular infiltrative breast cancers].
Chipysheva TA; Ermilova VD; Vishnevskaia IaV; Vasil'ev IuM
Arkh Patol; 2005; 67(6):24-7. PubMed ID: 16405017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
